ICRF 198
hydrolysis product of dexrazoxane; ADR-925 is the (S)-enantiomer of ICRF-198; structure given in first source; ADR 925 is identical to N,N'-((1S)-1-methyl-1,2-ethanediyl)-bis(N-(2-amino-2-oxoethyl))glycine
Also Known As:
ADR 925; ADR-925; ICRF 198, (+-)-isomer; ICRF-198; N,N'-((1S)-1-methyl-1,2-ethanediyl)-bis(N-(2-amino-2-oxoethyl))glycine
Networked: 7
relevant articles (0 outcomes,
2 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Hasinoff, Brian B:
2 articles
(08/2003 - 01/2002)
|
2. | Brázdová, Petra:
1 article
(01/2018)
|
3. | Bureš, Jan:
1 article
(01/2018)
|
4. | Chládek, Jaroslav:
1 article
(01/2018)
|
5. | Jirkovská, Anna:
1 article
(01/2018)
|
6. | Jirkovský, Eduard:
1 article
(01/2018)
|
7. | Karabanovich, Galina:
1 article
(01/2018)
|
8. | Kovaříková, Petra:
1 article
(01/2018)
|
9. | Lenčová, Olga:
1 article
(01/2018)
|
10. | Pokorná, Zuzana:
1 article
(01/2018)
|
Related Diseases
1. | Cardiotoxicity
01/01/2018
- " The aim of this study is to characterize the conversion and disposition of DEX to ADR-925 in vitro (primary cardiomyocytes) and in vivo (rabbits) under conditions where DEX is clearly cardioprotective against anthracycline cardiotoxicity. " 01/01/2000
- " It has been suggested that its hydrolysis product, ICRF-198, chelates and removes free iron and iron associated with doxorubiciniron complex and, therefore, prevents the formation of free radical, lipid peroxidation and cardiotoxicity. " 05/25/1993
- " They also imply that .OH production may not be as important in Adriamycin cardiotoxicity as other radical reactions, such as lipid peroxidation and thiol oxidation, that are inhibited by ICRF-198." 01/01/2018
- " Dexrazoxane (DEX), the only cardioprotectant approved against anthracycline cardiotoxicity, has been traditionally deemed to be a prodrug of the iron-chelating metabolite ADR-925. " 01/01/1997
- " Dexrazoxane reduces this cardiotoxicity, possibly by removal of iron from doxorubicin by the EDTA-like hydrolysis product of dexrazoxane, ADR-925. "
|
2. | Neoplasms (Cancer)
|
3. | Brain Neoplasms (Brain Tumor)
|
4. | Hypoxia (Hypoxemia)
|
|
Related Drugs and Biologics